TY - JOUR T1 - <em>Nab</em>-Paclitaxel Monotherapy as a Treatment of Patients with Metastatic Breast Cancer in Routine Clinical Practice JF - Anticancer Research JO - Anticancer Res SP - 3407 LP - 3413 VL - 33 IS - 8 AU - JULIA AIGNER AU - FREDERIK MARMÉ AU - KATHARINA SMETANAY AU - FLORIAN SCHUETZ AU - DIRK JAEGER AU - ANDREAS SCHNEEWEISS Y1 - 2013/08/01 UR - http://ar.iiarjournals.org/content/33/8/3407.abstract N2 - Aim: To compare treatment results with use of nab-paclitaxel in routine clinical practice with data obtained from clinical trials. Patients and Methods: A retrospective chart review of all 36 patients with metastatic breast cancer treated with nab-paclitaxel was performed. Nab-paclitaxel was given weekly and usually started at 150 mg/m2. Results: Thirteen (36.1%) patients received nab-paclitaxel as first-line, seven (19.4%) as second-line and 16 as third- or further line treatment. Overall, the response rate was 9.7%, disease control rate 64.5%, median progression-free survival 7.5 months and median overall survival 14.2 months. The most frequent non-hematological toxicities of grade 3 or more were fatigue (27.8%), dyspnea, rash and arthalgia (all 5.6%). Six (16.7%) patients developed peripheral neuropathy of grade 2 or more. Incidence of neutropenia grade 3 or more was 41.7% with no case of febrile neutropenia. Conclusion: According to our experience, weekly nab-paclitaxel is effective and tolerable, with results at least comparable to those from the prospective clinical trials. ER -